Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance

被引:63
作者
Hakooz, N
Ito, K
Rawden, H
Gill, H
Lemmers, L
Boobis, AR
Edwards, RJ
Carlile, DJ
Lake, BG
Houston, JB [1 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Cyprotex, Macclesfield SK10 2DR, Cheshire, England
[3] Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England
[4] Celltec Grp Plc, Slough SL1 3WE, Berks, England
[5] BIBRA Int Ltd, Carshalton SM5 4DS, Surrey, England
关键词
human hepatic microsomal scaling factor; prediction of clearance; variability in vitro;
D O I
10.1007/s11095-006-9531-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To determine a microsomal scaling factor for human liver Suitable for prediction of in vivo drug clearance from in vitro data and to explore the role of inter-liver variability in this factor oil the reported underprediction from microsomal parameters. Methods. Cytochrome P450 (henceforth P450) content in whole homogenates and microsomes from 38 donor livers was used to determine a microsomal scaling, factor. In subset (n = 20) of these preparations, individual P450 enzymes were examined by Western blotting and selective probe activities were determined. Results. The scaling factor front 38 livers averaged 40 mg microsomal protein per gram liver with a coefficient of variation of 31%. Western blotting experiments indicated that there was no P450 enzyme-specific trend in the distribution of individual P450 enzymes in liver microsomes relative to whole homogenate. Predictions based on an average scaling factor resulted in a satisfactory prediction of intrinsic clearance of three benzodiazepines similar to that obtained using individual factors for the same livers. Conclusion. A value for human liver microsomal scaling of 40 mg microsomal protein per gram liver has been established. The reason for underprediction previously reported tor 52 different drug substrates was not the use of an incorrect value for the scaling factor.
引用
收藏
页码:533 / 539
页数:7
相关论文
共 29 条
[1]  
BAARNHIELM C, 1986, ACTA PHARMACOL TOX, V59, P113
[2]  
Carlile DJ, 1997, DRUG METAB DISPOS, V25, P903
[3]   Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans [J].
Carlile, DJ ;
Hakooz, N ;
Bayliss, MK ;
Houston, JB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (06) :625-635
[4]   Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans [J].
Edwards, RJ ;
Adams, DA ;
Watts, PS ;
Davies, DS ;
Boobis, AR .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (03) :377-387
[5]   MICROSOMAL CYTOCHROME-P-450-LINKED MONOOXYGENASE SYSTEMS AND LIPID-COMPOSITION OF HUMAN HEPATOCELLULAR-CARCINOMA [J].
HAMAMOTO, I ;
TANAKA, S ;
MAEBA, T ;
CHIKAISHI, K ;
ICHIKAWA, Y .
BRITISH JOURNAL OF CANCER, 1989, 59 (01) :6-11
[6]  
HOUSTON JB, 1994, BIOCHEM PHARMACOL, V47, P1469
[7]   Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices [J].
Houston, JB ;
Carlile, DJ .
DRUG METABOLISM REVIEWS, 1997, 29 (04) :891-922
[8]   Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches [J].
Ito, K ;
Houston, JB .
PHARMACEUTICAL RESEARCH, 2005, 22 (01) :103-112
[9]   Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes [J].
Ito, K ;
Houston, JB .
PHARMACEUTICAL RESEARCH, 2004, 21 (05) :785-792
[10]   Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport [J].
Ito, K ;
Iwatsubo, T ;
Kanamitsu, S ;
Nakajima, Y ;
Sugiyama, Y .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 :461-499